Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNAP trial in Staphylococcus aureus bacteremia
NL-OMON59333Phase 4Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2023
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vancomycin in Staphylococcal bacteremia (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: All-cause mortality at 90 days. Started Oct 2023; status: recruiting.
02
Drugs
vancomycin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on NL-OMON59333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59333.